Abstract CN38
Background
Cardiovascular disease (CVD) mortality among cancer survivors is increasing with advances in cancer screening and treatment modalities. However, most studies have been conducted only in cancer cohorts, and evidence is limited regarding the risk of CVD mortality among cancer survivors compared with healthy populations, with possible mechanisms remaining unclear. This study aimed to comprehensively assess the risk of CVD mortality among cancer survivors compared to the healthy population and to explore the role of chronic low-grade inflammation in this process.
Methods
The study population was drawn from participants in the 2001-2014 National Health and Nutrition Examination Survey (NHANES). Cancer diagnosis was determined based on self-reported disease history, and mortality outcome was determined by the NHANES-linked National Death Index. The Fine and Gray competing risk model was conducted to assess the association between cancer and CVD mortality, and the association between the chronic low-grade inflammation (as assessed by the Chronic Low-Grade Inflammation Score) and CVD mortality among cancer survivors.
Results
The final study population consisted of 2803 cancer survivors and 25,376 healthy participants. With a median follow-up of 83 months, 141(3.14%) and 516 (1.27%) CVD deaths occurred in cancer survivors and healthy population, respectively. There was a higher risk of CVD death in cancer survivors than in the healthy population [HR (95% CI): 1.320 (1.085-1.605)], especially in breast cancer survivors [HR (95% CI): 2.036 (1.233-3.362)], independently of the common risk factors of cancer and CVD. Cancer survivors with the highest quartile of chronic low-grade inflammation levels suffered from an increased risk of CVD mortality compared to those with the lowest quartile [HR (95% CI): 2.337 (1.218-4.484)].
Conclusions
Cancer survivors, particularly breast cancer survivors, suffer an increased risk of CVD mortality compared with healthy populations, and chronic low-grade inflammation may be involved in this process. Further studies are needed to explore the impact of specific cancer treatments on CVD and the underlying mechanisms, so as to further improve the survival and quality of life of cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
CN62 - Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset gastric cancer: A retrospective cohort study on 18877 patients
Presenter: Yingxue Liu
Session: EONS Poster Display session
Resources:
Abstract
CN63 - Quality of life among parents of children with cancer
Presenter: Abeer Hussain
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN74 - Exploring the correlation between spiritual health, quality of survival, and meaning of life among breast cancer chemotherapy patients
Presenter: Fang Zhao
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN75 - Telehealth interventions and functional outcomes in breast cancer rehabilitation: A systematic review
Presenter: Marco Invernizzi
Session: EONS Poster Display session
Resources:
Abstract
CN76 - A study of sexual dysfunction in Moroccan female survivors of gynaecological cancer: A prospective study about 220 patients
Presenter: Chadia Ezzouitina
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN77 - ‘Eating with others’: Planning, developing and testing a self-management intervention to promote social eating for patients living with and beyond head and neck cancer
Presenter: Mark Dornan
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN79 - Quality-of-Life (QoL) data published by clinical trials supporting drug approvals for renal cell carcinoma (RCC)
Presenter: Rowanne Seadon
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN80 - Why do some patients undergoing laryngectomy for head and neck cancer opt to not reacquire their voice?
Presenter: Miyoko Iwai
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN81 - How to use a theoretical framework to inform intervention development in a breast cancer study?
Presenter: Sek Ying Chair
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN93 - Quality of life scale-based machine learning approach to predict immunotherapy response in patients with advanced non-small cell lung cancer
Presenter: Juanyan Shen
Session: EONS Poster Display session
Resources:
Abstract
Slides